TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort
暂无分享,去创建一个
D. Forman | J. Sloan | L. Murray | C. Wild | L. Hardie | M. Scott | A. Sedo | A. Sedo | D. Mcmanus | M. Scott | L. Murray
[1] C. Wild,et al. Risk Factors, DNA Damage, and Disease Progression in Barrett's Esophagus , 2005, Cancer Epidemiology Biomarkers & Prevention.
[2] D. Lane,et al. P53 abnormalities and outcomes in colorectal cancer: a systematic review , 2005, British Journal of Cancer.
[3] Patricia L. Blount,et al. The Combination of Genetic Instability and Clonal Expansion Predicts Progression to Esophageal Adenocarcinoma , 2004, Cancer Research.
[4] D. Meek,et al. The p53 response to DNA damage. , 2004, DNA repair.
[5] J. Prolla,et al. p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett's esophagus. , 2004, Cancer letters.
[6] L. Lovat,et al. Gastrin-Induced Cyclooxygenase-2 Expression in Barrett’s Carcinogenesis , 2004, Clinical Cancer Research.
[7] S. Meltzer,et al. Biomarkers of Esophageal Adenocarcinoma and Barrett’s Esophagus , 2004, Cancer Research.
[8] A. Gavin,et al. Risk of adenocarcinoma in Barrett's oesophagus: population based study , 2003, BMJ : British Medical Journal.
[9] Christopher P. Wild,et al. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions , 2003, Nature Reviews Cancer.
[10] R. Cestari,et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. incidence of dysplasia and adenocarcinoma: a prospective study , 2003, American Journal of Gastroenterology.
[11] A. Gavin,et al. Mortality in Barrett’s oesophagus: results from a population based study , 2003, Gut.
[12] A. Polednak,et al. Trends in survival for both histologic types of esophageal cancer in U.S. surveillance, epidemiology and end results areas , 2003, International journal of cancer.
[13] R. Playford,et al. Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK , 2003, Alimentary pharmacology & therapeutics.
[14] D. Vidaud,et al. Cyclooxygenase‐2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma , 2003, Histopathology.
[15] I. Johnson,et al. Cyclo‐oxygenase‐2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study , 2003, Alimentary pharmacology & therapeutics.
[16] S. Spechler,et al. Hallmarks of cancer progression in Barrett's oesophagus , 2002, The Lancet.
[17] J. Goldblum,et al. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression , 2002, American Journal of Gastroenterology.
[18] H. Barr,et al. Endoscopic surveillance of patients with Barrett’s oesophagus , 2002, Gut.
[19] G. Jenkins,et al. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma , 2002, The British journal of surgery.
[20] P. Dickman,et al. Improved survival in both histologic types of oesophageal cancer in Sweden , 2002, International journal of cancer.
[21] J. Goldblum,et al. Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation , 2002, American Journal of Gastroenterology.
[22] David Sidransky,et al. Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.
[23] Noel S Weiss,et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. , 2002, Gastroenterology.
[24] G. A. Meijer,et al. Surveillance in Barrett's Oesophagus: a Critical Reappraisal , 2002, Scandinavian journal of gastroenterology. Supplement.
[25] P. Blount,et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. , 2001 .
[26] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[27] Prateek Sharma,et al. p53 protein overexpression in low grade dysplasia (LGD) in barrett's esophagus: Immunohistochemical marker predictive of progression , 2001, American Journal of Gastroenterology.
[28] F. Bosman,et al. p53 Gene Mutation and Protein Accumulation during Neoplastic Progression in Barrett's Esophagus , 2001, Modern Pathology.
[29] R. DuBois,et al. Cyclooxygenase-2 Expression in Barrett's Esophagus , 2001, Digestive Diseases and Sciences.
[30] S. Attwood,et al. Cyclooxygenase-2 expression in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence , 2001, American Journal of Gastroenterology.
[31] R. Playford,et al. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study , 2000, BMJ : British Medical Journal.
[32] S. Groshen,et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. , 2000, Journal of the National Cancer Institute.
[33] F. Bosman,et al. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. , 2000, American journal of clinical pathology.
[34] D. Forman,et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. , 2000, Journal of the National Cancer Institute.
[35] G. Lapertosa,et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. A prospective study , 2000 .
[36] M. Omary,et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. , 2000, Gastroenterology.
[37] J. Bartelsman,et al. Surveillance of Barrett's oesophagus: physicians' practices and review of current guidelines , 2000, European journal of gastroenterology & hepatology.
[38] N. Powe,et al. Management of Barrett's esophagus: a national study of practice patterns and their cost implications , 1999, American Journal of Gastroenterology.
[39] B. Reid,et al. p53-mutant clones and field effects in Barrett's esophagus. , 1999, Cancer research.
[40] M. Younes,et al. p53 Protein Accumulation Is a Specific Marker of Malignant Potential in Barrett's Metaplasia , 1997, Digestive Diseases and Sciences.
[41] G. Viale,et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma , 1997, Cancer.
[42] G. Thomas,et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.
[43] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[44] J B Wong,et al. A guide for surveillance of patients with Barrett's esophagus. , 1994, The American journal of gastroenterology.
[45] D. Beer,et al. Intestinal differentiation and p53 gene alterations in barrett's esophagus and esophageal adenocarcinoma , 1994, International journal of cancer.
[46] F. Ellis,et al. Endoscopic surveillance of Barrett's esophagus. Does it help? , 1993, The Journal of thoracic and cardiovascular surgery.
[47] F. Duhaylongsod,et al. Barrett's esophagus and adenocarcinoma of the esophagus and gastroesophageal junction. , 1991, The Journal of thoracic and cardiovascular surgery.
[48] Carissa A. Sanchez,et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression , 2001, American Journal of Gastroenterology.
[49] T Mach,et al. [Barrett's metaplasia]. , 1999, Folia medica Cracoviensia.
[50] Dawn Provenzale,et al. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk , 1999, American Journal of Gastroenterology.
[51] P. Maxwell,et al. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. , 1998, British Journal of Cancer.
[52] H. Barr,et al. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. , 1998, The American journal of pathology.